Premium
Expression of phosphorylated signal transducer and activator of transcription 5 is associated with an increased risk of death in acute myeloid leukemia
Author(s) -
Brady Anna,
Gibson Sarah,
Rybicki Lisa,
Hsi Eric,
Saunthararajah Yogen,
Sekeres Mikkael A.,
Tiu Ramon,
Copelan Edward,
Kalaycio Matt,
Sobecks Ronald,
Bates Jennifer,
Advani Anjali S.
Publication year - 2012
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.2012.01825.x
Subject(s) - medicine , myeloid leukemia , stat protein , leukemia , bone marrow , myeloid , oncology , stat , phosphorylation , stat3 , biology , biochemistry
Background Constitutive activation of STAT 5 (by phosphorylation) has been identified in a number of malignancies, including acute myeloid leukemia ( AML ). Objectives We investigated whether the level of phosphorylated STAT 5 ( pSTAT 5) expression correlates with clinical outcome in AML . Methods Adult patients with newly diagnosed AML receiving induction chemotherapy and with an available diagnostic bone marrow were evaluated. Results Forty‐two percent of patients had pSTAT 5 expression >0 on immunohistochemical analysis of fixed bone marrow core biopsies. In multivariable analyses, controlling for age, history of antecedent hematologic disorder, cytogenetic risk, and WBC at diagnosis, pSTAT 5 expression was significantly associated with an increased risk of death ( HR 1.96, 95% CI 1.19–3.23, P = 0.008) and of relapse after achieving complete remission ( HR 2.31, 95% CI 1.16–4.63, P = 0.018). Conclusions Validation of pSTAT 5's prognostic value requires additional study in a larger group of uniformly treated patients. However, our data suggests that targeting this signaling pathway in AML may improve the outcome of patients.